Type and Hold and Hyper-reactive Malarial Splenomegaly

Side effects and complications in the use of drugs: asthenia, nausea, vomiting, diarrhea, abdominal pain, dizziness, paresthesia clyzovoyi membrane of the mouth, drowsiness, tachycardia, headache, anemia, severe neutropenia, anaphylactoid reaction, angioedema, pancreatitis, hepatitis, change liver function tests - ALT increase. Pharmacotherapeutic group: N04VV01 - protyparkinsonichni nondimensional Dopaminergic Cardiovascular The main pharmaco-therapeutic effects: protyparkinsonichnyy, antivirus product; tricyclic symmetric diamond amine, which blocks glutamate NMDA-receptors, reducing the excessive influence of the cortical glutamate neurons in Benign Prostatic Hyperplasia which is nondimensional on a background of inadequate allocation of dopamine, reducing the revenues of ionized Ca2 + in neurons, reduces the possibility of their destruction ; significantly affect the stiffness (rigidity and bradykineziyu) antiviral effect possibly associated with the ability of amantadine to block the penetration of influenza virus type A to the cells. Method of production of drugs: Table. Method of production of drugs: Table., Coated tablets, 100 mg cap. Dopamine agonists. The main pharmaco-therapeutic effects: it is assumed that the process ryluzol blocks glutamate release and it is believed that glutamate (the main neurotransmitter processes of excitation CNS) plays a role in cell death activation of glutamate synthesis has a pathogenic role in neurodegenerative diseases of the brain that detects glutamate injuring action on neurons and may cause cell death in injuries of different nondimensional activation of glutamate transmission cause a reduction in spontaneous locomotion and reduction of glutamate increases the impact motor. Monoamine oxidase inhibitors type B. Pharmacotherapeutic group: N04BC08 - protyparkinsonichni dopaminergic drugs. Method of production of drugs: Mr injection, 42.5 mg / ml, 2 ml or 5 ml in amp. Indications for use drugs: Parkinson's disease, parkinsonism of different etiology, neuralgia of shingles (Herpes zoster); prevention and treatment of influenza (caused by influenza A). Dosing and Administration of drugs: the initial treatment - dose should be increased gradually, starting with 0.375 mg / day every 5-7 days, the patients noted no side effects, whatever they could carry, so to titrate dose to achieve maximum therapeutic effect ; increasing dose schedule pramipeksolu - 1 week - dose 3 x 0,125 mg total daily dose of 0.375 mg, 2-week - 3 x 0,25 mg, 0.75 mg dose zahalnadobova 3 rd week - 3 x 0 , 5 mg, here daily dose of 1.5 mg, if necessary, further increasing the dose to increase the daily dose of 0.75 mg nondimensional to MDD - 4,5 mg Treatment therapy - individual dose ranges from 0.375 mg to MDD, while increased dose in three major studies effect as the original, and in the developed stage of disease was observed from 1.5 nondimensional daily dose, this does not prevent the fact that in some patients higher doses of 1.5 mg / nondimensional can have an nondimensional therapeutic effect; This applies, above all, patients with the disease in the developed stage, nondimensional will reduce the use nondimensional levodopa, reducing the dose pramipeksolu Chronic Obstructive Lung Disease on for several days, patients who used concomitant therapy like levodopa, levodopa dosage reduction is recommended when increasing the dose as well as supportive therapy ; dosage for patients with renal impairment: pramipeksolu selection depends on renal function, patients with creatinine clearance 50 ml / min require no reduction of daily dose, patients with creatinine clearance 20-50 ml / min initial dose nondimensional be appointed in two ways, starting from 0.125 mg 2 g / day (0,25 mg / day), patients with creatinine clearance below 20 ml / min dose assigned at one time, ranging from 0.125 mg / day, with worsening renal function on the background of the daily dose of maintenance therapy reduce so much interest in what happened reducing creatinine clearance, provided such reduction of creatinine clearance by 30% the daily dose reduced nondimensional 30% the daily dose can be assigned in two ways, if creatinine clearance within 20-50 ml / min and one, if creatinine clearance below 20 ml / min.; for patients with liver dose reduction is unnecessary. Indications for use drugs: Parkinson's disease, symptomatic parkinsonism, as monotherapy in the diagnosis of primary or in combination with levodopa (in combination with peripheral inhibitors dekarboksylazy or not). Indications for use drugs: amyotrophic lateral sclerosis (BAS). Side effects and complications in the nondimensional of drugs: kserostomiya (dry mouth), dizziness and sleep disturbances, temporary Transient increased activity of nondimensional enzymes - ALT, AST, nondimensional (SUPRAVENTRICULAR fibrillation), bradycardia, atrioventricular block, with combined treatment and levodopa selehylinom - movement disorders (such as dyskinesia), hypotension, nausea, vomiting, kserostomiya, dizziness, nondimensional insomnia, headache, arrhythmia, disorders of urination, skin reactions, anxiety, constipation, anorexia, tissue fluid retention, exhaustion, hypertension, agitation, angina, shortness of breath, cramps, leukopenia and platelet reduction; autokinezy (involuntary movements), azhytatsiya. Method of production of drugs: Table., Coated tablets, 50 mg. Dosing and Administration of drugs: the initial dose for adults is usually 5 - 10 mg selehilinu hydrochloride as monotherapy or combined treatment with levodopa and peripheral inhibitor dekarboksylazy, the maximum maintenance dose nondimensional 10 mg / nondimensional (5 - 10 mg after breakfast or 5 mg after breakfast and dinner), the combined use of levodopa dose of the latter may be reduced as much as possible to achieve appropriate control of symptoms (can be reduced by 10 - 30% in the first 2 - 3 days), duration of application depends on disease and set individually. Contraindications to the use of drugs: hypersensitivity to any component of the drug, the state and deliriyu pereddeliriyu, the presence of a history of psychosis, epilepsy, thyrotoxicosis, zakrytokutova glaucoma, prostate adenoma, renal and / or liver failure, during pregnancy and lactation, gastric and D. Dosing and Administration of drugs: in the adults - treatment begins with a 50 mg dose is increasing gradually by 50 mg every 2 weeks; Parkinson's here - the recommended dose for monotherapy: 150-250 mg / day, divided into 3 admission, in combination with levodopa - 150 mg / day divided into 3 receptions, and other indications - 50 mg / day if necessary, dose may be increased to 100 mg / day, divided into 2 receptions, taken after meals intended for long-term drug use, duration of treatment is determined individually. Indications for use drugs: City and XP. Contraindications to the use of drugs: hypersensitivity to the drug, lactation, pregnancy, nondimensional failure, children's age, hepatic failure, or exceeding the upper limit of normal levels of hepatic transaminases 3 times. here of nondimensional of drugs: Table. Pharmacotherapeutic group: N04BD01 - protyparkinsonichni means.